EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics

Atefeh Deris, Mahdi Sohrabi-Haghighat iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0282646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Atefeh Deris und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Arak University, Arak, Iran. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with metastatic castration-resistant prostate cancer (mCRPC) are divided into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. In the latter two groups, successful outcomes may not be achieved due to the development of drug-resistant cells in the tumor environment during treatment. To overcome this challenge, a secondary drug can be used to control the population of drug-resistant cells, potentially leading to a longer period of disease inhibition. This paper proposes using a combination of Docetaxel and Abiraterone in some polytherapy methods to control both the overall cancer cell population and the drug-resistant subpopulation. To investigate the competition and evolution of mCRPC cancer phenotypes, as in previous studies, the Evolutionary Game Theory (EGT) has been used as a mathematical modeling of evolutionary biology concepts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHumansMaleDocetaxelTaxoidsAndrostenesTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesAbiraterone Acetate

Substanzen

DocetaxelabirateroneTaxoidsAndrostenesAbiraterone Acetate

Autor:innen und Institutionen

  • Faculty of Science, Arak University, Arak, Iran.

ORCID-Profile: Mahdi Sohrabi-Haghighat

Zitieren

APA

Deris, A., & Sohrabi-Haghighat, M. (2023). Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. PLOS ONE. https://doi.org/10.1371/journal.pone.0282646

Vancouver

Deris A, Sohrabi-Haghighat M. Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. PLOS ONE. 2023. doi:10.1371/journal.pone.0282646

BibTeX
@article{Deris2023,
  author = {Deris, Atefeh and Sohrabi-Haghighat, Mahdi},
  title = {Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0282646}
}
Kostenlos starten →